Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annu...( Interim results from a Phase 2 clinic...),Health

Interim results from a Phase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly among bortezomib-naive patients. Of 14 evaluable bortezomib-naive patients, 57 percent achieved responses, including one patient with a complete response, two with very good partial responses and five with partial responses. Four additional patients achieved stable disease. Of 31 patients treated, 10 percent have received 12 cycles of treatment and have been enrolled in an extension study. Adverse events were generally mild and manageable. These data were presented by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation at Washington University School of Medicine in a poster titled "PX-171-004, a multicenter Phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update" (Abstract #8537).

Ruben Niesvizky, M.D., Associate Attending Physician, New York-Presbyterian Hospital and Associate Professor of Medicine at Weill Cornell Medical College presented preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients. The combination of carfilzomib and lenalidomide is well tolerated and encouraging response rates have been observed. Of 18 evaluable patients, 61 percent have achieved partial or minor responses, including three very good partial responses. Notably, responses occurred in the first 28-day cycle of treatment and initial responses have improved with continued therapy. A maximum-tolerated dose has not yet been established and dose-escalation continues. These data were presented today in a poster titled "PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory mul
'/>"/>